Ex parte CHAROENVIT et al. - Page 7




             Appeal No.  1999-1413                                                                                    
             Application 08/176,024                                                                                   

                           The state of the art to which the invention pertains is such that as of                    
                    this date passive immunization has not been used to prevent malaria in                            
                    humans and that there are no vaccines for active or passive immunization                          
                    that are accepted as being effective for prevention of P. vivax malaria.                          
                    Charoenvit et al. (Science 251) states that it has never been definitively                        
                    established in humans that circulating antibodies to the sporozoite of                            
                    Plasmodium can prevent infection.   Furthermore, Harris et al. establishes                        
                    the use of monoclonal antibodies for in vivo human therapy is art-recognized                      
                    to be highly experimental and unpredictable to those of skill in the art.   The                   
                    record contains no working examples relating to the use of the NVS3                               
                    antibody for treatment of P. vivax malaria in humans....                                          
                           The invention has been exemplified using the monkey model.                                 
                    However, the evidence obtained using the monkey model is not sufficient to                        
                    allow one of ordinary skill in the art to predict the ability to practice the                     
                    claimed invention for treatment of humans given that the monkey model used                        
                    to exemplify the claimed invention is not an art-accepted model which is                          
                    recognized as having a clear correlation with human efficacy for the                              
                    evaluation of agents for passive immunotherapy of malaria.                                        
                    On the other hand, the appellants argue that proof of efficacy in humans is not                   
             required, and that the monkey animal model tests disclosed in the specification are                      
             accepted by experts in the field.   Substitute Brief, pages 13-15.                                       
                    The specification provides a working example demonstrating efficacy of the                        
             claimed formulation in a nonhuman primate, the Saimiri monkey.  Example 3, pages 13-                     
             15.  In addition, the Hoffman Declaration of record provides an expert opinion that “most                
             experts in the field consider this monkey model to be the most reliable system for                       
             predicting what will occur in humans.”  Hoffman Declaration, page 6.  The Hoffman                        
             Declaration also cites long-held knowledge in the art of passive immunotherapy for acute                 
             malaria in human children.   Hoffman Declaration, pages 4-5.                                             

                                                          7                                                           





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  Next 

Last modified: November 3, 2007